tbuckley/cabot-search huggingface dataset:
Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)
Authors: Livio Pagano, Georg Maschmeyer, Frederic Lamoth, Ola Blennow, Alienor Xhaard, Manuela Spadea, Alessandro Busca, Catherine Cordonnier, Johan Maertens
Journal: Leukemia (2025)

At the 10th European Conference on Infections in Leukaemia (ECIL), the guidelines for antifungal prophylaxis in pediatric and adult patients with hematological malignancies (HM) were updated and some changes introduced. Regarding acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients undergoing remission induction chemotherapy, a B-II grading has been assigned to isavuconazole, micafungin, and caspofungin, based on non-randomized studies that have shown efficacy in preventing invasive fungal diseases (IFD). Regarding high-risk MDS patients treated with azacytidine, prophylaxis with posaconazole during the first four cycles of treatment is supported in the literature. Prophylaxis is not indicated in patients treated for myeloproliferative neoplasms (NPM), acute lymphoid leukemia (ALL), and Hodgkin lymphoma (HL). For patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), prophylaxis is not generally indicated. For patients with multiple myeloma (MM), prophylaxis is not indicated and the limited epidemiological data available do not support the use of prophylaxis in subjects treated with bispecific antibodies. For patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), no substantial changes were made, apart from the addition of isavuconazole with grading B-II in the post-engraftment period. In patients undergoing auto-HSCT, antifungal prophylaxis is not indicated. Previous ECIL guidelines did not include CAR-T cells. The expert panel proposes to endorse the use of anti-mold prophylaxis in high-risk patients during pre-infusion and post-infusion, while in low-risk patients, anti-yeast prophylaxis can be recommended (B-II). For pediatric hematology patients, based on newly published data, caspofungin received a B-I grading as mold-active prophylaxis. Moreover, patients with ALL with insufficient treatment response during induction therapy, and children older than 12 y.o are now considered at high risk for IFD and are recommended to receive antifungal prophylaxis.
Tailoring the Therapeutic Potential of Stem Cell Spheroid-Derived Decellularized ECM through Post-Decellularization BDNF Incorporation to Enhance Brain Repair
Authors: Ying-Chi Kao, Pei-Ching Yang, Yu-Ping Lin, Grace H Chen, Shao-Wen Liu, Chia-Hsin Ho, Shih-Chen Huang, Peng-Ying Lee, Linyi Chen, Chieh-Cheng Huang
Journal: Biomaterials (2025)
Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation
Authors: Eric Ravussin, Guillermo Sanchez-Delgado, Corby K Martin, Robbie A Beyl, Frank L Greenway, Libbey S O'Farrell, William C Roell, Hui-Rong Qian, Jing Li, Hiroshi Nishiyama, Axel Haupt, Edward J Pratt, Shweta Urva, Zvonko Milicevic, Tamer Coskun
Journal: Cell Metabolism (2025)
Protecting Africa's children from extreme risk: a runway of sustainability for PEPFAR programmes
Authors: Lucie Cluver, Gibstar Makangila, Susan Hillis, Joel-Pascal Ntwali-N'Konzi, Seth Flaxman, Juliette Unwin, Jeffrey W Imai-Eaton, Vuyelwa Chtimbire, Lorraine Sherr, Jane Ng'ang'a, Chris Desmond, Elona Toska, Olayinka Omigbodun, Oliver Ratmann, Galen Carey, Mary Mahy, Brian Honermann, John Stover
Journal: The Lancet (2025)
Drug-Induced Membranous Nephropathy
Authors: Rupali S. Avasare, Nicole K. Andeen, Laith F. Al-Rabadi, Kevin Burfeind, Laurence Beck
Journal: Journal of the American Society of Nephrology (2025)

Abstract There is a resurgence of interest in drug-induced membranous nephropathy due to the widespread availability of recently discovered culprit medications, such as lipoic acid supplements, mercury in skin lightening creams, and nonsteroidal anti-inflammatory drugs (NSAIDs) and the relationship between these drugs and newly described target antigens. The clinical syndromes associated with drug-induced membranous nephropathy are similar in that proteinuria ranges from low-grade to nephrotic-range and generally remits within months of drug cessation. Histology is notable for subepithelial deposits that are immunoglobulin G1 (IgG1) subclass predominant, sometimes with a unique segmental distribution. The two antigens associated with drug-induced membranous nephropathy are neural epidermal growth factor-like 1 (NELL1) and proprotein convertase subtilisin/kexin 6 (PCSK6). Notably, several of the culprit drugs contain one or more sulfhydryl groups that may have potential mechanistic relevance. Here we review past research investigations into mechanisms of membranous nephropathy associated with gold salts, penicillamine, and mercury and use these historical studies as the basis for formulating new hypotheses on how drugs might promote immune dysregulation and, ultimately, membranous nephropathy.
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study
Authors: L. Provenzano, M.V. Dieci, G. Curigliano, M. Giuliano, A. Botticelli, M. Lambertini, G. Rizzo, R. Pedersini, M. Sirico, N. La Verde, A. Gennari, A. Zambelli, A. Toss, M. Piras, M. Giordano, B. Tagliaferri, D. Generali, D. Sartori, D. Miliziano, A. Menichetti, F. Ligorio, C. Zurlo, G. Griguolo, P.P. Berton Giachetti, V. Faso, C. Corti, E. Chiappe, S. Scagnoli, S. Pisegna, C. Capasso, C. De Angelis, G. Arpino, C. Criscitiello, V. Guarneri, G. Pruneri, L. Mariani, C. Vernieri, G. Bianchini, E. Munzone, A. Marra, L. Boldrini, A. Carnevale Schianca, J. Katrini, M.S. Cona, V. Cantile, A. Grieco, M. Pirolo, M. Zappulo, M.A.R. De Giglio, M. Laganà, D. Cosentini, U. De Giorgi, A. Vingiani, A. Belfiore, G. Fotia, G. Mazzoli, C. Sposetti, A. Abate, V. Bianchessi, G. Capri, G.V. Bianchi, F. de Braud, P. Baili, G. Scaperrotta, C. Depretto, A. Lasagna, F. Jacobs, O. Ponzoni, S. Maccarone, C. Strina, S. Coccato, R. Coviello
Journal: Annals of Oncology (2025)
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.
Authors: P Grover, S N Lo, I Li, A M J Kuijpers, F Kreidieh, A Williamson, T Amaral, F Dimitriou, J Placzke, K Olino, M G Vitale, P Saiag, R Gutzmer, C Allayous, R Olofsson Bagge, J Mattsson, N Asher, T J Carter, T M Meniawy, A R Lawless, J A Czapla, L Warburton, C Gaudy-Marquest, J J Grob, R G Collins, E Zhang, J I Kessels, B Neyns, I Mehmi, O Hamid, M Julve, A J S Furness, K A Margolin, S Levi-Ari, J M Ressler, W Haque, M A Khattak, A Wicky, R Roberts-Thomson, A Arance, G Warrier, M D Schollenberger, P Parente, E Chatziioannou, E J Lipson, O Michielin, J S Weber, C Hoeller, J Larkin, M B Atkins, R Essner, D B Johnson, R J Sullivan, P Nathan, J Schachter, C Lebbe, P A Ascierto, H Kluger, P Rutkowski, R Dummer, C Garbe, P C Lorigan, E Burton, H A Tawbi, J Haanen, M S Carlino, A M Menzies, G V Long
Journal: Annals of Oncology (2025)
Comparing continuous micromixing and extrusion downsizing for PEGylated nanoliposomes remotely loaded with doxorubicin or the steroid pro-drug methylprednisolone hemisuccinate
Authors: Keren Turjeman, Alexander-Nicholas Egler-Kemmerer, Dima Shamrakov, Christine Paulus, Raphael Thiermann, Yechezkel Barenholz, Regina Bleul
Journal: Journal of Controlled Release (2025)
Dual-miRNA Guided in-vivo Imaging and Multimodal Nanomedicine Approaches for Precise Hepatocellular Carcinoma Differentiation and Synergistic Cancer Theranostics using DNA Hairpins and Dual-Ligand functionalized Zirconium-MOF Nanohybrids
Authors: Kun Wang, Siyu Jiang, Wanli Wang, Wansong Chen, Tianhan Kai
Journal: Biomaterials (2025)
NGS‐MRD negativity in post‐HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk
Authors: Krystof Seferna, Michael Svaton, Andrea Rennerova, Aneta Skotnicova, Leona Reznickova, Tatana Valova, Petr Sedlacek, Petr Riha, Renata Formankova, Petra Keslova, Lucie Sramkova, Jan Stary, Jan Zuna, Alexandra Kolenova, Cyril Salek, Jan Trka, Eva Fronkova
Journal: HemaSphere (2025)

Abstract Monitoring of minimal residual disease (MRD) after hematopoietic stem cell transplantation (HSCT) in patients with acute lymphoblastic leukemia (ALL) is vital for timely therapeutic intervention planning. However, interpreting low‐positive results from the current standard method, quantitative PCR (qPCR) of immunoglobulin and T‐cell receptor gene rearrangements (IG/TR), poses challenges due to the risk of false positivity caused by non‐specific amplification. We aimed to improve MRD detection specificity using the next‐generation amplicon sequencing (NGS) of IG/TR rearrangements for better relapse prediction. In pediatric and young adult ALL patients undergoing sequential post‐HSCT MRD monitoring, we prospectively re‐tested positive non‐quantifiable qPCR results with NGS‐MRD using the EuroClonality‐NGS approach. We were able to confirm 13 out of 47 (27.7%) qPCR positive results using the more specific NGS‐MRD method. Out of 10 patients with at least one MRD positivity confirmed by NGS, six relapsed (60%) 1–3.7 months after testing. Among 25 patients with all NGS‐MRD results negative, two relapses occurred (8%) after 5.1 and 12.1 months. One‐year RFS was 40% versus 96% and 3‐year OS was 33.3% versus 94.4% for the NGS‐positive and NGS‐negative groups, respectively. The difference was not attributable to a varying rate of therapeutic interventions. Six patients out of 14 who had immunosuppressive treatment tapered or received donor lymphocyte infusion in response to MRD positivity developed significant graft versus host disease, leading to one fatality. This underscores the importance of enhancing the post‐HSCT relapse risk prediction accuracy through NGS‐MRD testing to avoid unnecessary interventions.
Mitochondrial DNA released by senescent tumor cells enhances PMN-MDSC-driven immunosuppression through the cGAS-STING pathway
Authors: Ping Lai, Lei Liu, Nicolò Bancaro, Martina Troiani, Bianca Calì, Yuxin Li, Jingjing Chen, Prafull Kumar Singh, Rydell Alvarez Arzola, Giuseppe Attanasio, Nicolò Pernigoni, Emiliano Pasquini, Simone Mosole, Andrea Rinaldi, Jacopo Sgrignani, Shi Qiu, Pan Song, Yingrui Li, Maria Andrea Desbats, Azucena Rendón Ángel, Ricardo Pereira Mestre, Andrea Cavalli, Lucio Barile, Johann de Bono, Andrea Alimonti
Journal: Immunity (2025)
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
Authors: S Martín-Lluesma, U Dafni, K Vervita, D Karlis, G Dimopoulou, Z Tsourti, G Villacampa, V Galvao, J Lostes, E Muñoz-Couselo, M Rotxés, X Villalobos, S Muñoz, J B A G Haanen, I M Svane, J M Piulats, J Martin-Liberal, A Gros, G Coukos, E Garralda
Journal: Annals of Oncology (2025)
To EMT or not to EMT: Ablation of mesenchymal tumor cell lineages reveals the essential role of EMT in pancreatic cancer initiation and evolution
Authors: Jessica Peura, Calvin Johnson, Jason R. Pitarresi
Journal: Cancer Research (2025)

Abstract Epithelial-to-mesenchymal transition (EMT), a complex biological pathway that facilitates cellular plasticity, is used by tumor cells to enable metastasis and drug resistance. Our functional understanding of the impact of EMT on cancer has been limited by the lack of effective tools to ablate tumor cells as they become mesenchymal. In a recent study published in Nature, Perelli and colleagues used elegant genetically engineered lineage tracing and ablation strategies to track and eliminate tumor cells as they undergo EMT in pancreatic cancer. In a two-pronged approach, they queried the functional consequences of ablating EMT tumor cells before pancreatic ductal adenocarcinoma (PDAC) formation or in advanced PDAC tumors. These experiments collectively revealed that epithelial tumor cells only progress to low-grade lesions with minimal proliferative potential, while mesenchymal tumor cells undergo EMT early on to become malignant and metastasize. Profiling of mesenchymal tumor cell lineages revealed an altered chromatin landscape that leads to chromosomal instability (CIN) and disease progression. CIN is facilitated through complex structural rearrangements and chromothripsis, ultimately driving increased tumor heterogeneity and enhanced proliferation in EMT cells. This work reveals that EMT is an important driver of tumor heterogeneity and progression as a downstream consequence of CIN and provides mechanistic insight into how cellular plasticity can lead to genomic changes that drive disease progression.
SCD1 Inhibition Blocks the AKT-NRF2-SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma
Authors: Utsav Sen, Charles Coleman, Nishant Gandhi, Vrinda Jethalia, Deniz Demircioglu, Andrew Elliott, Ari M. Vanderwalde, Omar Hayatt, Elisa de Stanchina, Balazs Halmos, Patrick C. Ma, Mirela Berisa, Dan Hasson, Triparna Sen
Journal: Cancer Research (2025)

Abstract Concurrent inactivating mutations in STK11 and KEAP1 drive primary resistance to therapies, lead to worse outcomes in KRAS-mutated lung adenocarcinoma (KRASmut-LUAD) and are associated with metabolic alterations. Elucidation of the underlying biology of this aggressive LUAD subset is needed to develop effective treatments to improve patient outcomes. Our transcriptomic analysis of 5498 “real-world” KRASmut-LUADs demonstrated that STK11/KEAP1 co-mutation led to upregulation of fatty acid and redox signaling pathways and considerable enrichment of the metabolic genes SCD1 and SLC7A11. High expression of SCD1 and SLC7A11 predicted poor prognosis in KRASmut-patients. Transcriptomics, lipidomics, and kinase arrays in preclinical models demonstrated that SCD1 inhibition promoted ferroptosis, altered fatty acid metabolism, and downregulated SLC7A11 via AKT-GSK3β-NRF2 signaling. SCD1 inhibition caused appreciable tumor regression in xenografts and augmented the efficacy of the ferroptosis inducer erastin. Overall, this study provides insights into the role of the SCD1-SLC7A11 axis in regulating metabolic programming and predicting poor patient outcomes in a genetically defined subset of KRASmut-LUAD.
Bidirectional modulation of glycolysis using a multifunctional nanocomposite hydrogel promotes bone fracture healing in type 2 diabetes mellitus
Authors: Shengming Zhang, Weixian Hu, Yanzhi Zhao, Yuheng Liao, Kangkang Zha, Wenqian Zhang, Chenyan Yu, Jiewen Liao, Hui Li, Wu Zhou, Faqi Cao, Bobin Mi, Guohui Liu
Journal: Bioactive Materials (2025)
Association between maternal diabetes and neurodevelopmental outcomes in children: a systematic review and meta-analysis of 202 observational studies comprising 56·1 million pregnancies
Authors: Wenrui Ye, Cong Luo, Jun Zhou, Xisong Liang, Jie Wen, Jing Huang, Yu Zeng, Yinghua Wu, Yong Gao, Zhixiong Liu, Fangkun Liu
Journal: The Lancet Diabetes & Endocrinology (2025)
Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TN
Authors: Jeff P. Sharman, Miklos Egyed, Wojciech Jurczak, Alan P Skarbnik, Krish Patel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Marie Hughes, Laura Maria Fogliato, Yair Herishanu, Versha Banerji, George A. Follows, Patricia A Walker, Paolo Ghia, Ann MH Janssens, John C Byrd, Emmanuelle France Ferrant, Alessandra Ferrajoli, William G. Wierda, Catherine Wangui Wachira, Batul T. Suterwala, Paulo A Palhares de Miranda, Veerendra Munugalavadla, Chuan-Chuan Wun, Jennifer A. Woyach
Journal: Blood (2025)

Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for treatment of chronic lymphocytic leukemia. We present results from ELEVATE-TN (NCT02475681) after median follow-up of 74.5 months. Overall, 535 patients were randomized (acalabrutinib-obinutuzumab, n = 179; acalabrutinib, n = 179; chlorambucil-obinutuzumab, n = 177). Median age was 70 years, 63.0% had unmutated IGHV (uIGHV), 13.6% had del(17p) and/or mutated TP53, and 17% had complex karyotype (CK; ≥3 chromosomal abnormalities). Median progression-free survival (PFS) was not reached (NR) for acalabrutinib-obinutuzumab and acalabrutinib vs 27.8 months for chlorambucil-obinutuzumab (both P &amp;lt; .0001); estimated 72-month overall PFS rates were 78.0%, 61.5%, and 17.2%, respectively. Acalabrutinib-obinutuzumab resulted in improved PFS vs acalabrutinib monotherapy (hazard ratio [HR]: 0.58, P = .0229). Patients with uIGHV, del(17p) and/or mutated TP53, or CK had significantly improved PFS with acalabrutinib ± obinutuzumab vs chlorambucil-obinutuzumab (P &amp;lt; .0001, P ≤ .0009, and P &amp;lt; .0001 for both acalabrutinib-containing arms, respectively). Median overall survival (OS) was NR for all treatments, with significantly longer OS for acalabrutinib-obinutuzumab vs chlorambucil-obinutuzumab (HR: 0.62, P = .0349). Estimated 72-month OS rates were 83.9%, 75.5%, and 74.7% for acalabrutinib-obinutuzumab, acalabrutinib, and chlorambucil-obinutuzumab, respectively. Adverse events (AEs) occurring after &amp;gt;4 years were mostly grade 1-2. Rates of AEs, serious AEs, and events of clinical interest were similar between acalabrutinib-containing arms and consistent with the known safety profiles of acalabrutinib and obinutuzumab. Efficacy and safety of acalabrutinib-containing arms were maintained, with longer PFS in both acalabrutinib arms vs chlorambucil-obinutuzumab including in patients with high-risk features.
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up
Authors: Sherilyn A Tuazon, Andrew J. Portuguese, Margot J Pont, Andrew J Cowan, Gabriel O Cole, Blythe D Sather, Xiaoling Song, Sushma Thomas, Brent L. Wood, Michelle Lee Blake, Melissa G Works, Mazyar Shadman, Emily C. Liang, Qian Wu, Jenna M Voutsinas, Ted A Gooley, Cameron J Turtle, Brian G. Till, David G Coffey, David G Maloney, Stanley R. Riddell, Damian J Green
Journal: Blood (2025)
Defining radiological healing in perianal fistulising Crohn’s Disease: a TOpClass global expert Delphi consensus
Authors: Easan Anand, Jalpa Devi, David H. Ballard, Shivani Joshi, Phil Tozer, Ailsa Hart, Anna Antoniou, Parakkal Deepak, Jaap Stoker, Phillip Lung
Journal: Clinical Gastroenterology and Hepatology (2025)
Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis
Authors: Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Ruta Brazauskas, Temitope Oloyede, Matthew Bye, Doris K Hansen, Christopher J Ferreri, Ciara L Freeman, Aimaz Afrough, Larry D. Anderson, Binod Dhakal, Devender S. Dhanda, Lohith Gowda, Hamza Hashmi, Melanie J Harrison, Amani Kitali, Heather J Landau, Abu-sayeef Mirza, Pallavi Patwardhan, Muzaffar H Qazilbash, Saad Z Usmani, Krina K. Patel, Taiga Nishihori, Siddhartha Ganguly, Marcelo C. Pasquini
Journal: Blood (2025)
They Not Like Us: Evaluating the Diverse Strategies in Locally Advanced Rectal Cancer Treatment
Authors: Pratik Shah, Tony Philip
Journal: Journal of Clinical Oncology (2025)

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice .
Potential interactions of community-based acute care teams on the frequency of acute contacts with health-care systems: an interrupted time series analysis
Authors: Stine Emilie Junker Udesen, Annmarie Touborg Lassen, Jens Søndergaard, Nina Andersen, Søren Mikkelsen, Søren Bie Bogh
Journal: The Lancet Healthy Longevity (2025)
Corrigendum to “Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial” [Eur. Urol. 86 (2024) 552–562]
Authors: Andrew J Armstrong, Oliver Sartor, Johann de Bono, Kim Chi, Karim Fizazi, Bernd J Krause, Ken Herrmann, Kambiz Rahbar, Scott T Tagawa, Fred Saad, Tomasz M Beer, Jiwen Wu, Osvaldo Mirante, Michael J Morris
Journal: European Urology (2025)
Prophylactic antiviral therapy and all-cause mortality in cancer patients with hepatitis B e antigen-negative chronic hepatitis B virus infection receiving immunosuppressive therapy
Authors: Sheng Nie, Lisha Cao, Licong Su, Shiyu Zhou, Yanqin Li, Ruixuan Chen, Fan Luo, Qi Gao, Yuxin Lin, Zhixin Guo, Xin Xu, Guobao Wang
Journal: JNCI Journal of the National Cancer Institute (2025)

Abstract Background The survival benefits of prophylactic antiviral therapy for cancer patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who require immunosuppressive therapy (IST) remain unclear. The present study aims to evaluate the association of prophylactic antiviral therapy with all-cause and cause-specific mortality in cancer patients. Methods This multicenter, retrospective cohort study included cancer patients with HBeAg-negative chronic HBV infection who received IST between January 2012 and December 2022. Patients were divided into groups with or without prophylactic antiviral therapy with nucleos(t)ide analogues. The primary outcome was all-cause mortality within one-year and secondary outcomes included cancer-related mortality, liver-related mortality, and HBV reactivation (HBVr). Confounding factors in patients who did and not receive antiviral prophylaxis were balanced by propensity score overlap weighting. The associations between prophylactic antiviral therapy and outcomes were assessed by Cox proportional hazards models. Results Of the 3,677 cancer patients deemed eligible for inclusion, 1,541 (41.9%) initiated antiviral prophylaxis and 2,136 (58.1%) did not. After overlap weighting, prophylactic antiviral therapy was significantly associated with lower risks of all-cause mortality (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.70-0.96), cancer-related mortality (HR, 0.82; 95% CI, 0.69-0.97), and HBVr (HR, 0.49; 95%CI, 0.39-0.61) within one-year. Consistent results were found across various subgroups and multiple sensitivity analyses. Conclusions Initiation of prophylactic antiviral therapy was associated with significant reductions in mortality and HBVr within one-year in cancer patients with HBeAg-negative chronic HBV infection who received IST in real-world clinical practice.
Plasma Proteomic Profiling Reveals ITGA2B as A Key Regulator of Heart Health in High-altitude Settlers
Authors: Yihao Wang, Pan Shen, Zhenhui Wu, Bodan Tu, Cheng Zhang, Yongqiang Zhou, Yisi Liu, Guibin Wang, Zhijie Bai, Xianglin Tang, Chengcai Lai, Haitao Lu, Wei Zhou, Yue Gao
Journal: Genomics Proteomics & Bioinformatics (2025)